LYEL
Price
$11.04
Change
-$0.27 (-2.39%)
Updated
Oct 30 closing price
Capitalization
270.54M
10 days until earnings call
Intraday BUY SELL Signals
PGEN
Price
$6.94
Change
+$0.30 (+4.52%)
Updated
Oct 30 closing price
Capitalization
2.48B
3 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

LYEL vs PGEN

LYEL vs PGEN Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
LYEL vs. PGEN commentary
Nov 01, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LYEL is a StrongBuy and PGEN is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for LYEL with price predictions
Oct 30, 2026

LYEL in upward trend: price rose above 50-day moving average on October 29, 2026

LYEL moved above its 50-day moving average on October 29, 2026 date and that indicates a change from a downward trend to an upward trend. In 36 of 41 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on LYEL as a result. In 74 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.

The Moving Average Convergence Divergence (MACD) for LYEL just turned positive on October 15, 2026. Looking at past instances where LYEL's MACD turned positive, the stock continued to rise in 37 of 44 cases over the following month. The odds of a continued upward trend are 84%.

Following a +11.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where LYEL advanced for three days, in 201 of 240 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Bearish Trend Analysis

The 10-day RSI Indicator for LYEL moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In 19 of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LYEL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

LYEL broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for LYEL entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. LYEL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.157) is normal, around the industry mean (3.162). P/E Ratio (-0.870) is within average values for comparable stocks, (-1.064). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.622) among similar stocks. LYEL's P/S Ratio (10000.000) is very high in comparison to the industry average of (439.647).

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LYEL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for PGEN with price predictions
Oct 30, 2026

PGEN's RSI Indicator ascending out of oversold territory

The RSI Indicator for PGEN moved out of oversold territory on October 27, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 33 similar instances when the indicator left oversold territory. In 32 of the 33 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 64 of 70 cases where PGEN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on PGEN as a result. In 86 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 89%.

Following a +14.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where PGEN advanced for three days, in 206 of 241 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

PGEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for PGEN turned negative on October 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 41 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 75%.

PGEN moved below its 50-day moving average on October 15, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for PGEN crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

The Aroon Indicator for PGEN entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. PGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 73 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.

The Tickeron PE Growth Rating for this company is 83 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: PGEN's P/B Ratio (57.021) is slightly higher than the industry average of (3.162). P/E Ratio (-6.486) is within average values for comparable stocks, (-1.064). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.622) among similar stocks. P/S Ratio (32.258) is also within normal values, averaging (439.647).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
PGEN: Fundamental Ratings
PGEN
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
PROFIT vs RISK RATING
1..100
73
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
40
P/E GROWTH RATING
1..100
83
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
LYELPGEN
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
86%
Bullish Trend 3 days ago
89%
MACD
ODDS (%)
Bullish Trend 3 days ago
84%
Bearish Trend 3 days ago
75%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
85%
Bearish Trend 3 days ago
87%
Advances
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 3 days ago
85%
Declines
ODDS (%)
Bearish Trend 11 days ago
89%
Bearish Trend 7 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
88%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
87%
COMPARISON
Comparison
Nov 01, 2026
Stock price -- (LYEL: $11.04 vs. PGEN: $6.94)
Brand notoriety: LYEL and PGEN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LYEL: 85% vs. PGEN: 156%
Market capitalization -- LYEL: $270.54M vs. PGEN: $2.48B
LYEL [@Biotechnology] is valued at $270.54M. PGEN’s [@Biotechnology] market capitalization is $2.48B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $141.65B. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LYEL’s FA Score shows that 1 FA rating(s) are green while PGEN’s FA Score has 0 green FA rating(s).

  • LYEL’s FA Score: 1 green, 4 red.
  • PGEN’s FA Score: 0 green, 5 red.
According to our system of comparison, LYEL is a better buy in the long-term than PGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LYEL’s TA Score shows that 4 TA indicator(s) are bullish while PGEN’s TA Score has 5 bullish TA indicator(s).

  • LYEL’s TA Score: 4 bullish, 5 bearish.
  • PGEN’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, PGEN is a better buy in the short-term than LYEL.

Price Growth

LYEL (@Biotechnology) experienced а +17.57% price change this week, while PGEN (@Biotechnology) price change was +12.12% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.20%. For the same industry, the average monthly price growth was -14.01%, and the average quarterly price growth was -15.33%.

Reported Earning Dates

LYEL is expected to report earnings on Nov 11, 2026.

PGEN is expected to report earnings on Nov 04, 2026.

Industries' Descriptions

@Biotechnology (+0.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
LYEL
Daily Signal:
Gain/Loss:
PGEN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

LYEL and

Correlation & Price change

A.I.dvisor indicates that over the last year, LYEL has been loosely correlated with VCYT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if LYEL jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LYEL
1D Price
Change %
LYEL100%
-2.34%
VCYT - LYEL
46%
Loosely correlated
-4.14%
ABEO - LYEL
44%
Loosely correlated
-4.61%
SLDB - LYEL
44%
Loosely correlated
-2.97%
EDIT - LYEL
43%
Loosely correlated
-8.87%
TSHA - LYEL
43%
Loosely correlated
-2.13%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
BREW27.700.44
+1.62%
Corgi Coffee & Energy Drinks ETF (BREW)
NYM24.620.06
+0.22%
AB New York Intermediate Municipal ETF (NYM)
FUMB20.03N/A
+0.02%
First Trust Ultra Short Duration Municipal ETF (FUMB)
DRKY20.50-0.77
-3.64%
VistaShares Target 15 DRUKMacro Distribution ETF (DRKY)
CRDU4.96-1.01
-16.99%
Tradr 2X Long CRDO Daily ETF (CRDU)